Indiana University, Department of Psychological and Brain Sciences, 1101 E 10th St, Bloomington, IN 47405, United States.
Brown University School of Medicine, Department of Psychiatry and Human Behavior, United States.
J Affect Disord. 2018 Jul;234:8-13. doi: 10.1016/j.jad.2018.02.066. Epub 2018 Feb 27.
The generalizability of findings from studies exploring the efficacy of psychotherapy and antidepressants has been called into question in part because studies exclude many patients. Despite this, the frequency with which psychotherapy and antidepressant studies use specific inclusion and exclusion criteria has never been compared. We explored the exclusion criteria used in psychotherapy and pharmacotherapy studies from 1995 to 2014.
Systematic literature searches were conducted in PubMed, Medline, PsycINFO, and Embase of published randomized controlled trials (RCTs) of the treatment of major depressive disorder (MDD) in adults with either antidepressants (vs. placebos) or psychotherapy (vs. placebos, treatments as usual, or other controls).
Most psychotherapy (81%) and antidepressant (100%) trials excluded patients with milder symptoms as well as patients with elevated suicidal risk (56-75%), psychotic symptoms (84-88%), or substance misuse (75-81%). Psychotherapy studies were less likely to exclude patients on the basis of brief episode duration (0% vs. 48%) and co-morbid Axis I disorders (6% vs. 27%). However, psychotherapy studies excluded patients with more severe symptoms more frequently (38%) than antidepressant studies (8%).
Overall, psychotherapy studies appear somewhat more inclusive than antidepressant studies. On average, antidepressant studies appear to target patients with more chronic and severe, as well as more purely depressive presentations.
部分原因是研究排除了许多患者,因此探索心理治疗和抗抑郁药疗效的研究结果的普遍性受到了质疑。尽管如此,心理治疗和抗抑郁药研究使用特定的纳入和排除标准的频率从未被比较过。我们探讨了 1995 年至 2014 年期间心理治疗和药物治疗研究中使用的排除标准。
在 PubMed、Medline、PsycINFO 和 Embase 中进行了系统文献检索,以检索发表的成人重度抑郁症(MDD)抗抑郁药(与安慰剂相比)或心理治疗(与安慰剂、常规治疗或其他对照相比)治疗的随机对照试验(RCT)。
大多数心理治疗(81%)和抗抑郁药(100%)试验排除了症状较轻以及自杀风险升高(56-75%)、精神病症状(84-88%)或物质使用障碍(75-81%)的患者。心理治疗研究不太可能基于短暂发作持续时间(0%对 48%)和共病轴 I 障碍(6%对 27%)排除患者。然而,心理治疗研究更频繁地排除症状更严重的患者(38%),而不是抗抑郁药研究(8%)。
总体而言,心理治疗研究似乎比抗抑郁药研究更具包容性。平均而言,抗抑郁药研究似乎针对的是慢性和严重程度更高、更纯粹的抑郁表现的患者。